Association Between Bortezomib Therapy and Eyelid Chalazia

Fraunfelder, Frederick W.; Yang, Huiqi

doi:10.1001/jamaophthalmol.2015.3963

Cited by 28 publications

(15 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Three agents (bortezomib, pertuzumab, and dabrafenib) were associated with minor ocular adverse events according to the FDA label, but limited evidence of ocular toxicity was evident upon an independent survey of the literature. Multiple rigorous case reports have associated bortezomib with eyelid chalazia [ 14 – 16 ] and dabrafenib with uveitis and cystoid macula edema [ 17 ], however, due to lack of quantified trial data, these agents were excluded from Table 2 . Similarly, two agents (idelalisib and ibrutinib) were found to have adverse events from our literature review, but the FDA labels included no mention of ocular toxicity; these agents were excluded from Table 1 but were included in subsequent analysis.…”

Section: Resultsmentioning

confidence: 99%

Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions

Gombos

Lee

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Ocular toxicities are among the most common adverse events resulting from targeted anticancer agents and are becoming increasingly relevant in the management of patients on these agents. The purpose of this study is to provide a framework for management of these challenging toxicities based on objective data from FDA labels and from analysis of the literature. All oncologic drugs approved by the FDA up to March 14, 2015, were screened for inclusion. A total of 16 drugs (12 small-molecule drugs and 4 monoclonal antibodies) were analyzed for ocular toxicity profiles based on evidence of ocular toxicity. Trials cited by FDA labels were retrieved, and a combination search in Medline, Google Scholar, the Cochrane database, and the NIH Clinical Trials Database was conducted. The majority of ocular toxicities reported were low severity, and the most common were conjunctivitis and “visual disturbances.” However, severe events including incidents of blindness, retinal vascular occlusion, and corneal ulceration occurred. The frequency and severity at which ocular toxicities occur merits a more multidisciplinary approach to managing patients with agents that are known to cause ocular issues. We suggest a standardized methodology for referral and surveillance of patients who are potentially at risk of severe ocular toxicity.

show abstract

Section: Resultsmentioning

confidence: 99%

Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions

Gombos

Lee

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…In a large cohort of patients treated with bortezomib, chalazia was noted to occur in 2% of patients (Ganesh et al 2014). Chalazia occurrence is found to occur with a mean of three months after initiation of Bortezomib (Fraunfelder & Yang 2016). In this patient, the chalazia occurred after 10 weeks of commencing chemotherapy.…”

Section: Multiplementioning

confidence: 70%

“…In our patient, cessation of the chemotherapy mid-cycle due to severity of chalazia caused a repeat of his third chemotherapy cycle. Consequentially, bortezomib's association with chalazia has been characterized as a possible adverse drug reaction according to the World Health organization classification (Fraunfelder & Yang 2016). Recognization of this adverse reaction to bortezomib will allow earlier identification and appropriate co-management of the patient with the treating oncologist (Allen 2017).…”

Section: Multiplementioning

confidence: 99%

Recurrent Chalazia Secondary to Bortezomib

Hamzah¹

2018

View full text Add to dashboard Cite

ABSTRAKKes chalazia yang disebabkan oleh bortezomib pernah dilaporkan namun ia bukanlah dikenalpasti sebagai satu kesan sampingan kepada bortezomib. Kami dengan ini melaporkan kes chalazion yang berulang disebabkan rawatan bortezomib. Seorang pesakit lelaki berusia 40 tahun yang menghidap myeloma rantaian ringan telah mengalami chalazia di mata kiri dan meibominitis di keduadua belah mata selepas sepuluh minggu menerima rawatan kemoterapi dengan bortezomib. Walaupun dirawat, chalazia pesakit tidak pulih hingga menyebabkan rawatan bortezomib dihentikan. Setelah ubat doxycycline diberi, chalazia pesakit semakin pulih dan rawatan kemoterapi disambung, namun chalazia pesakit berulang kembali dan memerlukan incision & curretage. Rawatan dengan azithromycin telah mengecutkan chalazia pesakit tanpa perlu menghentikan kemoterapi. Hubungan antara bortezomib dan chalazia telah dicirikan sebagai reaksi ubat yang berkemungkinan menurut klasifikasi World Health Organization, dan pengiktirafannya sebagai reaksi ubat akan membolehkan pengenalan awal dan pengurusan bersama pesakit dengan pakar onkologi. ABSTRACTFew cases of chalazia secondary to bortezomib are reported in literature. However, it is not a recognized ocular adverse effect. We hereby report a case of recurrent chalazia secondary to bortezomib. A 40-year-old male with light chain myeloma on ten weeks of chemotherapy with bortezomib was treated for left eye inflamed

show abstract

“…A literature review done showed 28 cases of bortezomib induced blepharitis reported. Most recently, the association between bortezomib and chalazia was classified as a "possible" adverse drug reaction (ADR) based on the World Health Organization's definition of ADRs and an analysis of both case reports in the literature as well as reports submitted to the National Registry of Drug-Induced Ocular Side Effects [5,6].…”

Section: Case Reportmentioning

confidence: 99%

Bortezomib-Induced Blepharitis: a Case Report

2020

IJCRT

View full text Add to dashboard Cite

Introduction: Bortezomib is a proteasome inhibitor approved for the treatment of multiple myeloma, and has known manageable toxicities. Blepharitis is an inflammatory condition of the eyelid that leads to formation of chalazia both causing visual field disturbance. Bortezomib induced blepharitis has not been well reported in the literature. Case: we present a case of 76 year old lady with multiple myeloma who developed bortezomib-induced blepharitis and chalazia. Patient was successfully treated after topical ocular therapy, systemic antibiotherapy and omission of bortezomib.

show abstract

Association Between Bortezomib Therapy and Eyelid Chalazia

Cited by 28 publications

References 9 publications

Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions

Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions

Recurrent Chalazia Secondary to Bortezomib

Bortezomib-Induced Blepharitis: a Case Report

Contact Info

Product

Resources

About